oral semaglutide weight loss fda FDA-Approved Semaglutide: The First GLP-1 Pill The FDA has officially approved

TeSlaa T, Ralser M, Fan J, Rabinowitz JD

In the same announcement, Alnylam said it would no longer work toward an expanded label for the siRNA therapeutic in cardiomyopathy of ATTR amyloidosis in the U.S

[1] [2] The physiologic role of GLP-1 includes stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety through central nervous system pathways

Approved in December 2025, the pill delivers the efficacy of semaglutide with the convenience of a daily tablet

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued

Compounded GLP-1 and dual GIP/GLP-1 receptor agonists: A statement from the American Diabetes Association